Pharma Mar SA ( (PHMMF) ) has released its Q3 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharma Mar SA is a biotechnology company focused on the discovery and development of marine-derived drugs, primarily in the oncology sector, with a unique emphasis on leveraging compounds from the sea for therapeutic purposes.
In its latest earnings report for the first nine months of 2025, Pharma Mar SA announced a 3% increase in group revenue, reaching €130.9 million, compared to the same period in 2024. The company also highlighted significant milestones in its oncology and RNA interference (RNAi) segments, including FDA approval for its drug Zepzelca® in combination with Tecentriq® for small cell lung cancer treatment.
The company reported a 6% increase in recurring revenue, totaling €105.6 million, while non-recurring revenue saw a 7% decline. EBITDA for the period was €23.1 million, a significant improvement from the previous year. Notably, Pharma Mar received a $50 million milestone payment from Jazz Pharmaceuticals following FDA approval of Zepzelca®. Additionally, the company secured a €21.1 million grant from the European Commission for its subsidiary Sylentis under the IPCEI program.
Pharma Mar’s R&D expenditure decreased by 8% year-on-year, attributed to the completion of patient recruitment for key clinical trials. The company continues to invest in early-stage clinical development, prioritizing the development of PM54 over PM14 due to its superior efficacy and safety profile.
Looking ahead, Pharma Mar remains focused on advancing its clinical trials and exploring new therapeutic combinations, supported by a strong cash position of €100 million. The management is optimistic about the company’s growth prospects, driven by its innovative pipeline and strategic partnerships.